Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156353 | 0.83 | KMT2A (0.59) | MAPTEGFRPOLBTSHRUSP2 | |
| SCHEMBL2388693 | 0.82 | NOTUM (0.54) | MAPTPOLBNOTUMTSHRUSP2 | |
| SCHEMBL25916050 | 0.81 | ALDH1A1 (0.68) | PTGS2MAPTEGFRPOLBNOTUM | |
| SCHEMBL13572955 | 0.81 | TSHR (0.73) | MAPTEGFRPOLBTSHRUSP2 | |
| SCHEMBL14438048 | 0.81 | KMT2A (0.62) | PTGS2MAPTEGFRPOLBNOTUM | |
| SCHEMBL3032013 | 0.81 | MAPT (0.49) | MAPTPOLBNOTUMTSHRUSP2 | |
| SCHEMBL7260633 | 0.81 | NPC1 (0.64) | MAPTPOLBNOTUMTSHRUSP2 | |
| SCHEMBL8589773 | 0.81 | NPC1 (0.61) | PTGS2MAPTPOLBNOTUMTSHR | |
| SCHEMBL8235977 | 0.81 | ALDH1A1 (0.67) | MAPTPOLBNOTUMTSHRSMN1; SMN2 | |
| SCHEMBL12420283 | 0.81 | MAPT (0.45) | MAPTPOLBNOTUMTSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0435381-B1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA NV (BE) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5196535-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-23 | — | — | US | disclosed |
| US-5100893-A | Viricides, effective against picorna virus, durability | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-03-31 | — | — | US | disclosed |
| EP-0435381-A1 | Antipicornaviral pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | PTGS2 2017/4885MAPT 3673/4885EGFR 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.